A multi-year agreement between NRG and Curium has been signed for the production of Molybdenum-99, the base material for Technetium-99 (Tc 99m) generators. Tc 99m is the most important isotope used in nuclear medicine. This means that for doctors and hospitals worldwide the diagnosis of life-threatening diseases, such as cardiovascular, lung and brain diseases, as well as cancer, is supported for the long term, by combining NRG’s irradiation capabilities (highest number of full-power days globally) with Curium’s processing & manufacturing capabilities (global leader in nuclear medicine).
Some 49 million patient investigations with nuclear medicine are conducted annually, and Tc 99m, is used in more than 80% of these investigations. We expect the total market to grow, particularly for nuclear medicines used in the treatment of cancer. This agreement represents a major step towards meeting this growing demand.
Pierre Timmermans, CEO of NRG: “This contract confirms our continuing partnership. Petten maintains its world leading position to fulfil the demand for Molybdenum-99 and develop new therapeutic nuclear medicines”. Renaud Dehareng, CEO Curium: “This agreement confirms Curium’s long-standing relationship with NRG and supports our mission of providing life- saving diagnostic products for patients”.
Both NRG and Curium are located in Petten, and together they are the world’s largest suppliers of nuclear medicines. The production process complies with all nuclear safety and pharmaceutical requirements that apply today. In Petten, Molybdenum-99 is only produced from low-enriched uranium, as set forth by the Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). This confirms our support for the NNSA project to eliminate the use of weapons-grade uranium in the production of medical isotopes.